Developing in vitro expanded CD45RA⁺regulatory T cells as an adoptive cell therapy for Crohn's disease

Abstract

Background and aimThymus-derived regulatory T cells (Tregs) mediate dominant peripheral tolerance and treat experimental colitis. Tregs can be expanded from patient blood and were safely used in recent phase 1 studies in graft versus host disease and type 1 diabetes. Treg cell therapy is also conceptually attractive for Crohn's disease (CD). However, barriers exist to this approach. The stability of Tregs expanded from Crohn's blood is unknown. The potential for adoptively transferred Tregs to express interleukin-17 and exacerbate Crohn's lesions is of concern. Mucosal T cells are resistant to Treg-mediated suppression in active CD. The capacity for expanded Tregs to home to gut and lymphoid tissue is unknown.MethodsTo define the optimum population for Treg cell therapy in CD, CD4+CD25+CD127loCD45RA+ and CD4+CD25+CD127loCD45RA− Treg subsets were isolated from patients’ blood and expanded in vitro using a workflow that can be readily transferred to a good manufacturing practice background.ResultsTregs can be expanded from the blood of patients with CD to potential target dose within 22–24 days. Expanded CD45RA+ Tregs have an epigenetically stable FOXP3 locus and do not convert to a Th17 phenotype in vitro, in contrast to CD45RA− Tregs. CD45RA+ Tregs highly express α4β7 integrin, CD62L and CC motif receptor 7 (CCR7). CD45RA+ Tregs also home to human small bowel in a C.B-17 severe combined immune deficiency (SCID) xenotransplant model. Importantly, in vitro expansion enhances the suppressive ability of CD45RA+ Tregs. These cells also suppress activation of lamina propria and mesenteric lymph node lymphocytes isolated from inflamed Crohn's mucosa.ConclusionsCD4+CD25+CD127loCD45RA+ Tregs may be the most appropriate population from which to expand Tregs for autologous Treg therapy for CD, paving the way for future clinical trials.

Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease

“…25 Encouragingly, in vitro expansion of Treg now appears a viable option, with cells retaining their regulatory function, with stable FoxP3 expression. 26 The use of autologous Treg cell-based therapies avoids the possibility of graft versus host disease. Further understanding of human Treg-cell biology, particularly the disturbance in Treg/ Th17 differentiation and its modulation by puringeric signals, will greatly facilitate future development of therapeutics in this area.…”

AHR Activation Is Protective against Colitis Driven by T Cells in Humanized Mice

“…This critical role for IL-10 signaling in maintaining intestinal immune homeostasis is best exemplified by the observation that loss-of-function mutations in IL10 or the IL-10 receptor cause IBD in both mice and humans (Glocker et al, 2009; Kuhn et al, 1993). Since Tregs are thought to play a central role in preventing IBD (Josefowicz et al, 2012; Mayne and Williams, 2013; Sakaguchi et al, 2010), generation or expansion of functional Tregs constitutes an attractive therapeutic approach to treat IBD (Canavan et al, 2015) and therapeutic strategies aimed at expanding Tregs in vivo have proven effective in controlling other immune mediated disorders (Koreth et al, 2011; Saadoun et al, 2011) (Desreumaux et al, 2012). …”

Regulatory T cell therapy for type 1 diabetes: May the force be with you

“…Further efforts are underway in other autoimmune settings (Table 2), including the same ex vivo expanded polyclonal Treg cell product utilized in our adult T1D Phase I Planning study for a phase I study with active cutaneous lupus (NCT02428309) and pemphigus vulgaris. An ovalbumin-specific Treg phase I/IIa trial has been conducted in inflammatory bowel disease [82], and polyclonal Tregs are also being considered for a future study [83]. In mice, pre-activated polyclonal Tregs injected into the vitreous control autoimmune uveitis, and this approach is now being evaluated in a phase I study (NCT02494492) [84].…”